Insider Cluster (2 insiders) ·Filed Jun 5, 2026

XERS

Xeris Biopharma Holdings, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed3mo ago
Insider cluster: 2 insiders, $192K total
Actionable Insight • Neutral

The selling is immaterial in size and lacks C-suite participation, suggesting routine portfolio management. The larger director grants on June 4 signal board alignment. Monitor for any upcoming earnings or pipeline catalysts that could move the stock, but this cluster alone does not warrant action.

DirectionNeutral
Confidencemedium
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
XERS ▲ +35.10% at T+60d
NEUTRAL call ✓ call won +35.10% · α vs SPY +32.04% · entry $6.24 → $8.43
Entry anchored
Jun 5, 2026
via day open
T+1d
+4.17%
call +4.17% · α +4.46%
$6.50
settled 4mo ago
T+5d
+10.26%
call +10.26% · α +8.14%
$6.88
settled 4mo ago
T+20d
+34.13%
call +34.13% · α +32.50%
$8.37
settled 3mo ago
T+60d
+35.10%
call +35.10% · α +32.04%
$8.43
settled 4w ago

Price Chart

Loading chart...

Executive Summary

Two Xeris insiders (Director Persky and officer Hecht) sold a combined $192K in open-market sales over a 3-day window. The sales are modest relative to the $1.1B market cap (0.017%), and the cluster includes multiple director grants/awards on June 4 that offset the selling. The selling is likely liquidity-driven and not indicative of bearish conviction.

Key Financial Metrics

Direction
selling
Total Value
$192.0K
Insiders
2

Key Facts

  • Director Persky sold 15,500 shares at $5.90 for $91K on June 3
  • Officer Hecht sold 16,667 shares at $6.06 for $101K on June 1
  • Total open-market sales: $192K, or ~0.017% of $1.1B market cap
  • On June 4, four directors received grants/awards totaling $812K in value (non-cash plus deemed cash at $6.15)
  • No C-suite executives (CEO/CFO) participated in the selling

Financial Impact

Open-market sales of $192K represent 0.017% of market cap — trivial

insider ownership

Risk Factors

  • Insider selling could accelerate if stock price appreciates further
  • No material negative signal from this cluster — risk of over-interpreting noise

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-XERS-1780698596780
14 reports for XERS
Performance horizon
100% Hit rate 4 of 4 directional calls best @ T+60▲ +24.89%Jun 12, 2026
Filters
Rows
Reports for XERS — sortable, filterable
TypeNow
Sep 9, 2026
23d ago
8-K
BULLISH ★ 6/10
$7.71 $7.78▲ +0.91%▲ +1.56%$9.08 (+17.77%)
Sep 1, 2026
4w ago
Insider Cluster
NEUTRAL ★ 3/10
$8.58 $7.67▼ −10.61%▼ −9.65%$9.08 (+5.83%)
Aug 6, 2026
8w ago
8-K
BULLISH ★ 7/10
$7.36 $8.33▲ +13.18%▲ +11.97%$9.08 (+23.37%)
Aug 4, 2026
8w ago
Insider Cluster
NEUTRAL ★ 2/10
$8.19 $8.39▲ +2.44%▲ +2.54%$9.08 (+10.87%)
Jul 7, 2026
12w ago
Insider Cluster
BEARISH ★ 4/10
$8.94 $8.28▲ +7.38%▲ +7.93%$9.08 (−1.57%)
Jul 2, 2026
13w ago
3
NEUTRAL ★ 3/10
$8.28 $8.62▲ +4.11%▲ +3.18%$9.08 (+9.66%)
Jul 2, 2026
13w ago
Insider Cluster
NEUTRAL ★ 4/10
$8.28 $8.62▲ +4.11%▲ +3.18%$9.08 (+9.66%)
Jun 30, 2026
13w ago
8-K
NEUTRAL ★ 2/10
$8.00 $8.94▲ +11.75%▲ +11.49%$9.08 (+13.50%)
Jun 12, 2026
16w ago
Institutional Cluster
BULLISH ★ 4/10
$6.79 $6.95▲ +2.36%▲ +1.68%$9.08 (+33.73%)
Jun 5, 2026
17w ago
Insider Cluster
NEUTRAL ★ 3/10
$6.24 $6.88▲ +10.26%▲ +8.14%$9.08 (+45.51%)
Showing 10 of 14

US Market Status

Market Closed — Opens Mon (38h 30m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jun 5, 2026